Jyong Biotech Ltd. SEC filings MENS
Jyong Biotech Ltd. has 73 filings in SEC EDGAR's recent list, going back to Mar 16, 2023. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Feb 6, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F | Annual report (foreign issuer) | May 15, 2026 | Dec 31, 2025 |
| NT 20-F | Notification of late filing | Apr 29, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 6, 2026 | Feb 6, 2026 |
| 6-K | Current report (foreign issuer) | Jan 9, 2026 | Jan 9, 2026 |
| SP 15D2 | Filing | Jun 30, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Jun 20, 2025 | Jun 18, 2025 |
| 424B4 | Prospectus | Jun 18, 2025 | — |
| EFFECT | Filing | Jun 16, 2025 | — |
| CERT | Filing | Jun 16, 2025 | — |
| 8-A12B | For registration of certain classes | Jun 12, 2025 | — |
| CORRESP | Letter to the SEC | Jun 12, 2025 | — |
| CORRESP | Letter to the SEC | Jun 12, 2025 | — |
| POS AM | Registration statement | Jun 6, 2025 | — |
| POS AM | Post-effective amendment | Apr 23, 2025 | — |
| EFFECT | Filing | Mar 31, 2025 | — |
| CORRESP | Letter to the SEC | Mar 28, 2025 | — |
| CORRESP | Letter to the SEC | Mar 28, 2025 | — |
| FWP | Free writing prospectus | Mar 27, 2025 | — |
| FWP | Free writing prospectus | Mar 27, 2025 | — |
| F-1/A | Registration statement | Mar 11, 2025 | — |
| FWP | Free writing prospectus | Feb 18, 2025 | — |
| FWP | Free writing prospectus | Feb 7, 2025 | — |
| F-1/A | Registration statement | Feb 6, 2025 | — |
| F-1/A | Registration statement | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 18, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2024 | — |
| CORRESP | Letter to the SEC | Nov 21, 2024 | — |
| F-1/A | Registration statement | Nov 21, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2024 | — |
| F-1/A | Registration statement | Nov 1, 2024 | — |
| CORRESP | Letter to the SEC | Oct 31, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2024 | — |
| CORRESP | Letter to the SEC | Oct 4, 2024 | — |
| F-1/A | Registration statement | Oct 4, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 26, 2024 | — |
| F-1/A | Registration statement | Sep 16, 2024 | — |
| CORRESP | Letter to the SEC | Sep 13, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| F-1/A | Registration statement | Aug 2, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| F-1/A | Registration statement | Jun 21, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 8, 2024 | — |
| F-1/A | Registration statement | May 8, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2024 | — |
| F-1 | Registration statement (foreign issuer) | Mar 7, 2024 | — |
| RW | Withdrawal request | Dec 20, 2023 | — |
| CORRESP | Letter to the SEC | Dec 5, 2023 | — |
| F-1/A | Registration statement | Dec 5, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 10, 2023 | — |
| CORRESP | Letter to the SEC | Oct 18, 2023 | — |
| F-1/A | Registration statement | Oct 18, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 14, 2023 | — |
| CORRESP | Letter to the SEC | Aug 17, 2023 | — |
| F-1 | Registration statement (foreign issuer) | Aug 17, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2023 | — |
| DRSLTR | Filing | Jul 5, 2023 | — |
| DRS/A | Filing | Jul 5, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2023 | — |
| DRSLTR | Filing | May 22, 2023 | — |
| DRS/A | Filing | May 22, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2023 | — |
| DRS | Filing | Mar 16, 2023 | — |
Showing 65 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MENS (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- New Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1954488
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.